A Regimen of Taxol, Ifosfamide, and Platinum for Recurrent Advanced Squamous Cell Cancer of the Anal Canal

Table 1

Summary of patient characteristics and treatment outcomes with TIP.

Patient	Stage at original diagnosis	Treatment at original diagnosis	Presentation at recurrence	Treatment at recurrence	Toxicity besides alopecia with TIP: all were NCI grade 1 or 2 unless otherwise specified	Best response to TIP by RECIST criteria	Duration of response with TIP	Survival since recurrence
Case 1-46-year-old female	T3N3M0	CRT with 5FU/cisplatin	Biopsy-proven metastatic disease in chest and abdomen twelve months after original diagnosis	TIPx6 cycles then TIPx2 cycles then FOLFOX6 modified x1 cycle	Anemia Thrombocytopenia PN (grade 3)	CR per CT after 3 cycles confirmed by PET/CT after 3 more cycles	6 months	14 months
Case 2-42-year-old female	T3N3M0	CRT with 5FU/cisplatin	Biopsy-proven metastatic disease in chest twenty two months after original diagnosis	TIPx6 cycles	Anemia Thrombocytopenia; Diarrhea; Syncope; PN	CR per PET/CT after 3 cycles	2 years and six months	2 years and six months thus far
Case 3-54-year-old female	T4N2M0	CRT with 5FU/cisplatin	Metastatic disease in pelvis five months after original diagnosis	TIPx7 cycles then RT to right paraspinal mass	Anemia Thrombocytopenia Nausea	CR per PET after 4 cycles (PR per CT)	4 months	17 months thus far (patient alive with disease)

CRT: chemo radio therapy
5FU: fluorouracil
CR: complete remission
PR: partial remission
RECIST: response evaluation criteria in solid tumors
FOLFOX: infusional fluorouracil + leucovorin + oxaliplatin.
PN: Peripheral neuropathy.